Home FOR AUTHORS Neoplasma 2008 Neoplasma Vol.55, No.3, p.165-176, 2008

Journal info


6 times a year.
Founded: 1954
ISSN 0028-2685
ISSN 1338-4317 (online)

Published in English

Editorial Info
Abstracted and Indexed
Submission Guidelines

Select Journal







Webshop Cart

Your Cart is currently empty.

Info: Your browser does not accept cookies. To put products into your cart and purchase them you need to enable cookies.

Neoplasma Vol.55, No.3, p.165-176, 2008

Title: Wnt signaling and cancer development: therapeutic implication
Author: S. PAUL, A. DEY

Abstract: Wnt proteins are a large family of secreted glycoproteins that activate signal transduction pathways to control a wide variety of cellular processes such as determination of cell fate, proliferation, migration, and polarity. Wnts are capable of signaling through several pathways, the best-characterized being the canonical beta-catenin/Tcf-mediated pathway. Canonical Wnts stabilize β-catenin protein, which has implications in the genesis of many human cancers like non-small cell lung cancer, colorectal carcinoma, prostate cancer, breast cancer and many others. In all of these cancers the common denominator is the activation of target genes. Although detailed mechanisms are not well understood of why Wnts are overexpressed in one tumor and down regulated in another, the pleiotropism of Wnt signaling is evident. The pathway itself offers ample targeting nodal points for cancer drug development. The identification of many important regulatory genes and the mechanism of their function offer an opportunity to develop new therapies targeting this pathway. In this review, we describe the roles of several oncogenes of the Wnt/β-catenin signaling pathway in the development of tumorigenesis and discuss few strategies that are already developed or can be explored to target key components of the Wnt/ β-catenin signaling pathway in finding of anti-cancer drugs.

Keywords: Wnt signaling, Oncogene, β-Catenin, Neoplasm, Tumorigenesis, Colorectal cancer, Prostate cancer, Anti cancer drug.
Year: 2008, Volume: 55, Issue: 3 Page From: 165, Page To: 176

Price: 28.80 €






© AEPress s.r.o
Copyright notice: For any permission to reproduce, archive or otherwise use the documents in the ELiS, please contact AEP.